Alto Neuroscience develops precision medicines for neuropsychiatric conditions using an AI-driven biomarker platform to predict clinical responses and identify patients most likely to benefit from their drug candidates. Their focus on major depressive disorder, bipolar depression, and schizophrenia aims to replace the trial-and-error approach in psychiatric treatment with targeted therapies based on deep neurobiological insights.
Funding
$59.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current psychiatric treatment often relies on a trial-and-error approach, leading to delays in finding effective medications for patients with neuropsychiatric conditions. This can result in prolonged suffering and increased healthcare costs due to ineffective treatments and repeated clinical visits.
Solution
Alto Neuroscience is developing precision medicines for neuropsychiatric conditions by leveraging an AI-driven biomarker platform to predict individual patient responses to their drug candidates. Their approach focuses on identifying patients most likely to benefit from specific treatments, thereby reducing the trial-and-error nature of current psychiatric care. By using deep neurobiological insights, Alto aims to create targeted therapies for conditions like major depressive disorder, bipolar depression, and schizophrenia, leading to faster and more effective treatment outcomes. The company's clinical-stage drug candidates are designed to target core brain processes, offering alternative treatment options based on individual patient biology.
Target Audience
The primary target audience includes individuals suffering from major depressive disorder, bipolar depression, and schizophrenia, as well as psychiatrists and healthcare providers seeking more effective and targeted treatment options for their patients.
Features
- AI-driven biomarker platform for predicting clinical response to drug candidates.
- Focus on identifying patients most likely to benefit from specific treatments.
- Clinical-stage drug candidates targeting core brain processes in neuropsychiatric conditions.
- Development of targeted therapies for major depressive disorder, bipolar depression, and schizophrenia.
- Utilizes deep neurobiological insights to personalize treatment approaches.